Cogent Biosciences (COGT) announced updated clinical results from the Open Label Extension OLE, portion of SUMMIT, a clinical trial evaluating bezuclastinib in patients with nonadvanced systemic mastocytosis. The OLE data are being presented at the 66th American Society of Hematology Annual Meeting & Exposition taking place December 7-10, 2024 in San Diego, CA. Updated clinical data presented today show: 56% mean improvement in Total Symptom Score at 24 weeks; 76% of patients demonstrated greater than50% reduction from baseline in MS2D2 Total Symptom Score with 88% of patients exceeding 30% reduction from baseline after 24 weeks; 49% mean improvement in MC-QoL Total Score at 24 weeks. Bezuclastinib showed rapid, deep, and sustained reductions in serum tryptase over the course of 24 weeks of treatment including: 89% of patients had greater than50% decrease in serum tryptase levels by four weeks of treatment; 95% of patients with baseline tryptase greater than or equal to20ng/mL achieved less than20ng/mL by week 24; 84% of patients with baseline serum tryptase greater than11.4ng/ml achieved less than11.4ng/mL by week 24.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on COGT:
- Cogent Biosciences announces updated data from ongoing Phase 2 APEX trial
- Cogent Biosciences price target raised to $21 from $19 at JPMorgan
- Cogent Biosciences Reports Progress in Clinical Trials and Financial Standing
- Cogent Biosciences reports Q3 EPS (64c), consensus (57c)
- COGT Upcoming Earnings Report: What to Expect?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
